Investorplace: GW Pharmaceuticals’ Epidiolex was successful in reducing seizures in patients with Dravet syndrome, a form of epilepsy, by 39% over a 14-week period in its phase 3 trial. The study included 120 patients, 60 of which were given a placebo, with the average age being 10 years old.
Following its successful phase 3 trial for Epidiolex, GW Pharmaceuticals said that it’s looking for 150 patients to take part in a second phase trails of the drug. If more trails are successful, it’s possible that Epidiolex could be the first drug approved in the U.S. to treat Dravet syndrome.
Dravet syndrome, also known as severe myoclonic epilepsy of infancy (SMEI), is a type of epilepsy with seizures that are often triggered by hot temperatures or fever.
Operating margin (%) -304.90
Net-margin (%) -242.80
Revenue $34 million (USD)
Profits -$84 million
Join and see Pictures in https://www.facebook.com/groups/SeekingValue/